Medicare Add-On Payments For Praxbind, Andexanet Under Consideration
This article was originally published in The Pink Sheet Daily
Executive Summary
Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.